P1.01-20 Phase III Study Comparing Gefitinib (G) to Gefitinib Combined With Carboplatin and Pemetrexed (GCP) for NSCLC With EGFR Mutations (NEJ009)

Journal of Thoracic Oncology - United States
doi 10.1016/j.jtho.2018.08.576
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

P066 a Phase I Study of Apatinib Combined With Pemetrexed and Carboplatin in Untreated EGFR-Negative Stage IV Non-Squamous NSCLC

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P1.01-38 a Phase II With a Lead-In Phase I Study to Examine Safety and Efficacy of Hydroxychloroquine and Gefitinib in Advanced NSCLC

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P1.01-104 Updated Phase I Results of Carboplatin, Pemetrexed and Exemestane in Postmenopausal Women With Metastatic Non-Squamous NSCLC

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Learning From Errors: Response to Gefitinib in Kidney Urothelial Carcinoma With EGFR Mutations

Oncologist
Cancer ResearchMedicineOncology
2014English

P1.01-81 Phase 3 Study of Pemetrexed-Platinum With or Without Pembrolizumab for TKI-Resistant/EGFR-Mutated Advanced NSCLC: KEYNOTE-789

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P1.01-25 Carboplatin and Pemetrexed Plus Bevacizumab After Failure of First-Line EGFR-TKI Therapy for NSCLC Harboring EGFR Mutation (CJLSG 0908)

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Shikonin Sensitizes Wild‑type EGFR NSCLC Cells to Erlotinib and Gefitinib Therapy

Molecular Medicine Reports
OncologyGeneticsMolecular BiologyBiochemistryCancer ResearchMolecular Medicine
2018English

P1.01-92 a Phase II Study of Afatinib Treatment for Elderly Patients With Previously Untreated Advanced NSCLC Harboring EGFR Mutations

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P1.01-54 a Phase I/Ib Study of Binimetinib (MEK162), a MEK Inhibitor Plus Carboplatin/Pemetrexed in Non-Squamous NSCLC

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy